Rationale and algorithm for below-the-knee acute gain optimization

Similar documents
Efficacy of DEB in Calcification and Subintimal Angioplasty

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Provisional T- sten/ng Future Outlook: Ra/onale of Plaque Incision + DCB

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD

PHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS

Latest Insights from the LEVANT II study and sub-group analysis

The Utility of Atherectomy and the Jetstream Atherectomy System

ILLUMENATE FIH Direct DCB Cohort 12-Month Results

Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions

Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD

Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy

Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease

Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

Dierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany

Innovation by design. Technology that sets a new standard

Update on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria

Atherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System

INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please OTW PERIPHERAL DRUG COATED BALLOON CATHETER

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

The essentials for BTK procedures: wires, balloons, what else

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany

IVUS Guided Case Review Case Performed by Frank R. Arko III, MD Charlotte, NC

William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA

BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration

Michael K.W. Lichtenberg, MD

Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?

Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry

New approaches for drug delivery in BTK arteries

One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller

Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?

Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data

CLI Treatment Using Long and Scoring Balloons

Vessel Preparation Prior to DCB and Stenting: How to Do It.

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD

Atherectomy: Jetstream and Directional. George S. Chrysant, M.D.

Update on the role of drug eluting balloons

Utility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography

Complex PCI. Your partner in complex PCI: In-stent restenosis (ISR)

Drug- Coated Balloons for the SFA: Overview of Technology and Results

Are Drug-coated balloons Durable? Level 1 evidence review. Koen Keirse, MD Vascular Surgery, RZ Tienen Tienen, Belgium

New Data to Shape the Era of Drug Elution in Peripheral Interventions

RANGER SFA REGISTRY Interim Analysis. Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators

Drug-coated balloons in BTK:

Klinikum Rosenheim Department of Diagnostic and Interventional Radiology

Is a Stent or Scaffold Necessary in The SFA?

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

Management of In-stent Restenosis after Lower Extremity Endovascular Procedures

Adventitial Drug Therapy Below-the-Knee: Update on LIMBO and TANGO

Konstantinos Katsanos, MSc, MD, PhD, EBIR. Consultant Interventional Radiologist Guy's and St.Thomas' Hospitals, NHS Foundation Trust

COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert

Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND

TOBA Trial 12 months Results

Device Evolution. Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance. Where Do We Stand? 4/18/2015

Endovascular Options in Critical Limb Ischemia: Below The Knee Therapies

MEET M. Bosiers K. Deloose P. Peeters. SFA stenting in 2009 : The good and the ugly What factors influence patency?

Initial Clinical Experience with a Novel Dedicated Cobalt Chromium Stent for the Treatment of Below-the-knee Arterial Disease

The LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint

Lessons learnt from DES in the SFA is there any ideal concept so far?

Basics of Angiographic Interpretation Analysis of Angiography

IN ARTERIOVENOUS FISTULA FAILURE

Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁

Intravascular Imaging Insights into the Mechanism of Action of Focal Force Balloon Angioplasty

Neuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology

MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together

Appropriate Device Selection for Endovascular Procedures

Contemporary use of DCBs, Ranger clinical trial and investigator sponsored research

Turbo-Power. Laser atherectomy catheter. The standard. for ISR

Adventitial Drug Therapy for Critical Limb Ischemia

First time data release: Initial experience with the temporary Spur Stent System: DEEPER Trial first-in-man results Jihad A. Mustapha, MD, FACC,

Update on the Ranger clinical trial programme

Luminor DCB in femoropopliteal lesions

Is there still any space left for DES in the BTK area??? (Angiolite BTK trial, 6 month Data)

Alternative concepts for drug delivery in BTK arteries the LIMBO project

Shockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis

Michael K. W. Lichtenberg MD, FESC on behalf of KANSHAS 1 investigators; Tepe G, Müller-Hülsbeck S, Deloose K, Verbist J, Goverde P, Zeller T

DISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.

Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA

Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-

Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

Next Generation of DCB: Efficacy and tolerance of drug-coated hyper-compliant balloons (DCHCB) in peripheral arteries of swine

Intervention for Lower Extremity PAD: When, why and what?! Robert F Cuff, MD FACS RVT RPVI

Accurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery

Role of Covered Stents and Drug Eluting Balloons In Dialysis Access

In-Stent Restenosis: New Evidence From Laser + Drug Coated Balloons

New Evidence from Laser + Drug Coated Balloons for Treatment of In-Stent Restenosis

Present & future of below the knee stenting

Peripheral Arterial Disease: A Practical Approach

The latest generation DEB

2.4 mm deflecting 2.4 mm tracking Above the knee Phoenix Below the knee 2.2 mm tracking 1.8 mm tracking

SFA CTO Lesion Management laser or directional atherectomy?

4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters

Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis

Superficial Femoral Artery Intervention: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA

NC EMERGE TM PTCA Dilatation Catheter

Transcription:

Leipzig, 01 Feb. 2018 Rationale and algorithm for below-the-knee acute gain optimization Flavio Airoldi, MD Flavio Airoldi Multimedica IRCCS Milan ITALY flavio.airoldi@multimedica.it

Rationale Restenosis following PTA of BTK arteries is a multifattorial process which includes: Acute recoil Neointimal proliferation Late recoil flavio.airoldi@multimedica.it

Rationale Restenosis following PTA of BTK arteries is a multifattorial process which includes: Paclitaxel Acute recoil Neointimal proliferation Late recoil flavio.airoldi@multimedica.it

Rationale Restenosis following PTA of BTK arteries is a multifattorial process which includes: Paclitaxel Neointimal proliferation Acute recoil Late recoil Less relevant Stents??? flavio.airoldi@multimedica.it

Rationale: early recoil Early failures may be the leading cause of late failures 97% of tibial dilatation show early recoil: 29% lumen narrowing @ 15 minutes post intervention 2,5 2 1,5 1 0,5 MLD (mm) 0,23 2 15 minutes 1,47 0 baseline immediate post-poba 15 min post-poba Baumann F, et al. Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. J Endovasc Ther. 2014;21:44-51

Rationale: early recoil Early failures may be the leading cause of late failures -inflation time 1 minute -angiografic vessel size estimation: average 2.6 mm Baseline PTA Post-PTA 15 min Post-PTA Baumann F, et al. Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia.; J Endovasc Ther. 2014;21:44-51

Algorithm for BTK acute gain optimization - Correct vessel sizing: IVUS 1:1 ratio according to IVUS media to media distance -Scoring balloon AngioSculpt, Philips -Multiple prolonged inflations Four 90 sec. inflations with 90 rotation of the scoring balloon (total 6 min)

AngioSculpt Device Overview 3 Scoring elements Nitinol helical configuration rectangular edges semi-compliant balloon Lengths: 10 to 200 mm Diameters: 2.0 to 8.0 mm Nominal / RBP: 6-8/ 12-20 Intr. Sheath compatibility: 5 / 6 F Guidewire compatibility: 0.014 / 0.018

Plaque Scoring Rationale Controlled dissections by focal plaque incision, focal stress concentration Increase and stabilize luminal gain ( recoil) Reduce likelihood of flow-limiting dissections Confer precision and stability to balloon dilatation Potentially increase DCB drug uptake 1. Fonseca A, et al. Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions. J Invasive Cardiol. 2008;20:21-7 2. de Ribamar Costa Jr., et al. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. Am J Cardiol. 2007;100:812-7 3. Scheinert D, et al. Results of the multicenter first-in-man study of a novel scoring balloon catheter for the treatment of infra-popliteal peripheral arterial disease. Catheter Cardiovasc Interv. 2007;70:1034-9

Algorithm for BTK acute gain optimization Angiogram Standard PTA (angio based balloon choice ) Angio & IVUS (I) AngioSculpt PTA (4 inflations, total 6 min.) Angio & IVUS (II) 15 minutes STUDY END-POINT Angio & IVUS (III)

First end point: minimal lumen diameter MLD (mm) by automatic quantitative analysis (QCA) Baseline Angio- Post-PTA Post-PTA Sculpt 15 min

Algorithm for BTK acute gain optimization IVUS Post AngioSculpt IVUS 15 min. post AngioSculpt Second endpoint: vessel volume (mm 3 ) by intravascular ultrasound analysis (IVUS)

BTK acute gain optimization: angio measurements Post AngioSculpt 15 min post AngioSculpt Balloon size (mm) RVD MLD RVD MLD 3.0 (40%) 3.5 (60%) 2.9 ±0.4 2.7 ±0.5 2.9 ±0.4 2.7 ±0.3 mm N=5 lesions, 4 patients

BTK acute gain optimization: IVUS measurements Post AngioSculpt Vessel lumen volume 15 min post AngioSculpt Vessel lumen volume 623 ±34 614 ±42 mm 3 N=5 lesions, 4 patients Average length 88±24 mm I-Lab Boston Sc. IVUS System

Pre-dilatation 3.0 mm Standard balloon Lumen volume 516 mm 3 Final dilatation 3.0 mm AngioSculpt balloon Lumen volume 631 mm 3

Pre-dilatation 3.0 mm Standard balloon Plaque rupture

Plaque Scoring Rationale You can break a glass in different ways

Conclusions - The results of standard balloon angioplasties of BTK vessels may be jeopardized by acute vessel recoil -The combination of correct vessel sizing, scoring balloon angioplasty and multiple prolonged inflations may increase the acute gain and minimize acute vessel recoil. -The role of these strategy in association with DEB technologies should be explored in future studies.

Leipzig, 01 Feb. 2018 Rationale and algorithm for below-the-knee acute gain optimization Flavio Airoldi, MD Flavio Airoldi Multimedica IRCCS Milan ITALY flavio.airoldi@multimedica.it

Dissections and DCB Severe, non-flow limiting dissections do not negatively impact DCB outcomes THUNDER post-hoc analysis N=86 (43 DCB + 43 PTA) 6-month LLL (mm) by Angio Core laboratory 24-month TLR (%) p=0.02 p=0.05 p=0.001 p=0.1 p=0.02 p=0.002 Tepe G, Zeller T, Schnorr B, Claussen CD, Beschorner U, Brechtel K, Scheller B, Speck U. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013 Dec;20(6):792-800

Balloon Angioplasty Mode of Action Uncontrolled dissections, uncontrolled injury to break circumferential tensions (hoop stress) The traumatic effect of balloon dilatation: what we did not see before optical coherence tomography LAD showing the distal (A), mid (B) and proximal (C) segment of the stent after paclitaxel-coated balloon dilatation Picchi A, Micheli A, Limbruno U. Images in cardiology. The traumatic effect of balloon dilatation on neointimal hyperplasia: what we did not see before optical coherence tomography. Heart. 2011 Feb;97(3):265-6